1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited

Suven Pharmaceuticals Limited

SUVENPHAR.BO
Suven Pharmaceuticals LimitedIN flagBombay Stock Exchange
1,075.30
INR
- -
- -
411.37BMarket Cap

Total Valuation

Suven Pharmaceuticals Limited carries a market capitalization of 411.37B, placing it among publicly traded companies globally. Its enterprise value stands at 296.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap411.37B
Enterprise Value296.04B

Share Statistics

Suven Pharmaceuticals Limited currently has 254.56M shares outstanding.

Shares Outstanding254.56M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Suven Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 111.40. The price-to-sales ratio is 24.61, and the price-to-book ratio stands at 1,157.54.

PE Ratio111.40
PS Ratio24.61
PB Ratio1,157.54
P/TBV Ratio26.27
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Suven Pharmaceuticals Limited trades at an EV/EBITDA multiple of 99.44 and an EV/FCF ratio of 3,113.62. The EV/Sales ratio of 24.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 99.44 provides insight into valuation relative to core operating earnings.

EV / Sales24.72
EV / EBITDA99.44
EV / EBIT99.44
EV / FCF3,113.62

Financial Position

Suven Pharmaceuticals Limited maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.16, indicating elevated leverage, while an interest coverage ratio of 24.11 demonstrates strong ability to service its debt obligations.

Current Ratio2.43
Quick Ratio0.80
Debt / Equity15.16
Debt / EBITDA0.94
Interest Coverage24.11

Financial Efficiency

Suven Pharmaceuticals Limited posts a return on equity of 29.13 and a return on invested capital of 10.82.

Return on Equity (ROE)29.13
Return on Assets (ROA)10.01
Return on Invested Capital (ROIC)10.82
Return on Capital Employed (ROCE)23.75
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.67

Taxes

Over the trailing twelve months, Suven Pharmaceuticals Limited has paid 791.50M in income taxes, reflecting an effective tax rate of 23.01.

Income Tax791.50M
Effective Tax Rate23.01

Stock Price Statistics

Suven Pharmaceuticals Limited's stock has gained approximately 43.97804% over the past 52 weeks. The 50-day moving average sits at 1,093.16, while the 200-day moving average is 1,153.91.

Beta (5Y)N/A
52-Week Price Change43.97804%
50-Day Moving Average1,093.16
200-Day Moving Average1,153.91
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Suven Pharmaceuticals Limited generated 11.98B in revenue and converted that into 2.65B in net income, yielding earnings per share of 10.37. EBITDA reached 2.98B, while operating income came in at 2.98B.

Revenue11.98B
Gross Profit8.65B
Operating Income2.98B
Pretax Income3.44B
Net Income2.65B
EBITDA2.98B
EBIT2.98B
Earnings Per Share (EPS)10.37

Balance Sheet

Suven Pharmaceuticals Limited holds 2.90B in cash and equivalents against 2.79B in total debt, resulting in a net debt position of -72.70M. Total book value stands at 254.60M, with working capital of 5.23B providing operational flexibility.

Cash & Cash Equivalents2.90B
Total Debt2.79B
Net Debt-72.70M
Equity (Book Value)254.60M
Book Value Per Share1.00
Working Capital5.23B

Margins

Suven Pharmaceuticals Limited operates with a gross margin of 72.25, reflecting its pricing power and cost economics. The operating margin of 24.86 and net profit margin of 22.09 provide insight into operational efficiency.

Gross Margin72.25
Operating Margin24.86
Pretax Margin28.72
Profit Margin22.09
EBITDA Margin24.86

Stock Splits

Suven Pharmaceuticals Limited's most recent stock split took place on September 25, 2020 with a 1:2 split ratio.

Last Split Date9/25/2020
Split Ratio1:2

Scores

Suven Pharmaceuticals Limited posts an Altman Z-Score of 16.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.06